{
    "2021-02-08": [
        [
            {
                "time": "",
                "original_text": "康泰生物(300601.SZ)拟向不特定对象发行可转债募集不超过20亿元",
                "features": {
                    "keywords": [
                        "康泰生物",
                        "可转债",
                        "募集资金",
                        "20亿元"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药",
                        "生物"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "康泰生物(300601.SZ)拟发行不超过20亿元可转债投向百旺信应急工程建设项目和腺病毒载体新冠疫苗车间项目",
                "features": {
                    "keywords": [
                        "康泰生物",
                        "可转债",
                        "百旺信",
                        "新冠疫苗",
                        "腺病毒载体"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药",
                        "生物",
                        "疫苗"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "康泰生物：最近5年不存在被证监部门和交易所采取监管措施或处罚及整改情况",
                "features": {
                    "keywords": [
                        "康泰生物",
                        "监管措施",
                        "处罚",
                        "整改"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药",
                        "生物"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "康泰生物：拟发行可转债募资不超过20亿元",
                "features": {
                    "keywords": [
                        "康泰生物",
                        "可转债",
                        "募资",
                        "20亿元"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药",
                        "生物"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "医药生物行业周报：第四批国采结果公布 长期看好创新与高景气细分领域",
                "features": {
                    "keywords": [
                        "医药生物",
                        "第四批国采",
                        "创新",
                        "高景气细分领域"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "true",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药",
                        "生物"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "医药生物行业简评报告：全球疫情控制趋势向好 医药需求逐步“回正”",
                "features": {
                    "keywords": [
                        "医药生物",
                        "疫情控制",
                        "医药需求",
                        "回正"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药",
                        "生物"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "医药周报：板块回暖 新冠疫苗信息更新带动疫苗板块表现强势",
                "features": {
                    "keywords": [
                        "医药",
                        "板块回暖",
                        "新冠疫苗",
                        "疫苗板块"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药",
                        "疫苗"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "医药生物行业：第二款国产新冠疫苗获批上市 看好疫苗大时代背景下的新冠增量",
                "features": {
                    "keywords": [
                        "医药生物",
                        "新冠疫苗",
                        "获批上市",
                        "疫苗大时代"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药",
                        "生物",
                        "疫苗"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "医药行业周报：第四批集采落地 持续看好创新及相关产业链CXO",
                "features": {
                    "keywords": [
                        "医药",
                        "第四批集采",
                        "创新",
                        "CXO"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "true",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}